﻿<?xml version="1.0" encoding="UTF-8"?>
<records>
  <record>
    <language>eng</language>
    <publisher>Science and Education Publishing</publisher>
    <journalTitle>International Journal of Celiac Disease</journalTitle>
    <eissn>2334-3486</eissn>
    <publicationDate>2023-09-04</publicationDate>
    <volume>11</volume>
    <issue>1</issue>
    <startPage>36</startPage>
    <endPage>37</endPage>
    <doi>10.12691/ijcd-11-1-8</doi>
    <publisherRecordId>IJCD20231118</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">Celivir: A Viral Therapy for the Autoimmune Celiac Disease</title>
    <authors>
      <author>
        <name>Jose Crespo-Barrios</name>
        <email>
        </email>
        <affiliationId>1</affiliationId>
      </author>
    </authors>
    <affiliationsList>
      <affiliationName affiliationId="1">Free of Affiliation</affiliationName>
    </affiliationsList>
    <abstract language="eng">With an average of 1/200 affected people around the world, celiac disease still lacks a cure. Here a concept of a viral therapy with certain design degrees of freedom is suggested to the scientific community with the hope that a well experienced and equipped research team is able to endeavour such project. Also, safety concerns of the viral therapy about escape mutations and trophism are covered. These ideas can be extended to any autoimmune disease with an etiological alteration of the memory T-cells, paving the way to safer alternatives to the immunological reboot.</abstract>
    <fullTextUrl format="pdf">http://pubs.sciepub.com/ijcd/11/1/8/ijcd-11-1-8.pdf</fullTextUrl>
    <keywords language="eng">
      <keyword>celiac</keyword>
      <keyword>autoimmunity</keyword>
      <keyword>viral therapy</keyword>
      <keyword>escape mutation</keyword>
    </keywords>
  </record>
</records>